LYO-X AG

LYO-X AG, founded in 2014 and headquartered in Switzerland, specializes in providing strategic consulting and PK/PD modelling services for the preclinical and clinical development of biologics and cell-based therapies. The company's expertise lies in the development of biologics at the scientific forefront, including bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, and cell-based therapies. LYO-X applies systems pharmacology to offer tailored support for diverse therapeutic approaches, covering target assessment, compound design, preclinical PK/PD and GLP toxicology studies, as well as dose selection and pediatric drug development. The company's clientele includes biotechnology start-ups, pharmaceutical companies, and CROs. LYO-X is an integral part of the iBx Network, which offers integrated services in toxicology, pharmacology, preclinical and clinical development, combined with modelling and simulation. With its focus on cutting-edge drug formats and scientific expertise, LYO-X holds a unique position in the pharmaceutical consulting space. For potential investors in the venture capital sphere, LYO-X represents an opportunity to be involved in the advancement of novel biologics and innovative therapies, catering to the growing demand for specialized consulting in this domain. With the potential for further funding and strategic partnerships, LYO-X presents an intriguing prospect for investors seeking opportunities in the evolving biopharmaceutical landscape. For more information, visit www.lyo-x.com.